1303973-22-9

Usage

Uses

Used in Pharmaceutical Synthesis:
AMMDP is used as a key intermediate in the production of various drugs, particularly in the development of antiviral and antitumor medications. Its unique structure and reactivity contribute to the creation of effective pharmaceutical compounds.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, AMMDP is utilized as a versatile tool for drug discovery. Its potential biological activities make it a compound of interest for researchers working on new therapeutic agents.
Used in Academic Laboratories:
AMMDP is also employed in academic settings for research purposes, where its properties are explored and harnessed for the advancement of chemical and pharmaceutical sciences.
Used in Organic Chemistry:
As a building block in organic chemistry, AMMDP is instrumental in the synthesis of complex organic molecules, contributing to the development of novel chemical entities with potential applications in various industries.

Upstream product

• 1373503-45-7 N-(tert-butoxy)carbonyl-3,3-difluoro-4-(benzyloxycarbonylaminomethyl)piperidine 
• 1334412-95-1 tert-butyl 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidine-1-carboxylate 
• 1373503-54-8 (±)-2-(1-( tert-butoxycarbonyl)-3,3-difluoropiperidin-4-yl)acetic acid 
• 1373503-45-7 (R)-tert-butyl 4-((((benzyloxy)carbonyl)amino)methyl)-3,3-difluoropiperidine-1-carboxylate 
• 1373503-45-7 (S)-tert-butyl 4-((((benzyloxy)carbonyl)amino)methyl)-3,3-difluoropiperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1373503-54-8 (R)-2-(1-(tert-butoxycarbonyl)-3,3-difluoropiperidin-4-yl)acetic acid 
• 1067914-83-3 tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate 

Relevant academic research and scientific papers

TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS

Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

1-R 1 -3, 3-difluoro-4-R 2-piperidine and its derivatives preparation method

The invention relates to a preparation method for 1-R1-3,3-difluoro-4-R2-piperidine shown as a formula (I) and derivatives thereof. In the formula (I), R1 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R4 is C1-C9 alkyl, aryl or benzyl; R5 is C1-C9 alkyl, aryl or benzyl; R2 is CH2NHR6 or CH2CO2H; R6 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R3 is hydrogen, C1-C9 alkyl, aryl or benzyl; and the above optional groups are not substituted or substituted by a substituted group consisting of one or more of alkyl, haloalkyl, hydroxyalkyl, halogen, alkyloxy or hydroxyl. The preparation method is characterized by comprising steps shown by a reaction formula in the specification.

3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).